Kiniksa Pharmaceuticals Statistics
Want to see KNSA full AI Analyst Report?
Kiniksa Pharmaceuticals (KNSA) Stock Statistics & Valuation Metrics
Total Valuation
Kiniksa Pharmaceuticals has a market cap or net worth of $7.56B. The enterprise value is $5.78B.
- Market Cap
- $7.56B
- Enterprise Value
- $5.78B
Share Statistics
Kiniksa Pharmaceuticals has 48,836,964 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 48,836,964
- Owned by Insiders
- 8.29%
- Owned by Institutions
- 55.32%
Financial Efficiency
Kiniksa Pharmaceuticals’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 8.17%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 8.17%
- Return on Capital Employed (ROCE)
- 0.12
- Revenue Per Employee
- 1.85M
- Profits Per Employee
- 161.22K
- Employee Count
- 366
- Asset Turnover
- 0.89
- Inventory Turnover
- 5.60
Valuation Ratios
The current PE Ratio of Kiniksa Pharmaceuticals is 67.36. Kiniksa Pharmaceuticals’s PEG ratio is 0.35.
- PE Ratio
- 67.36
- PS Ratio
- 8.00
- PB Ratio
- 10.61
- Price to FCF
- 38.38
- Price to Operating Cash Flow
- 37.88
- PEG Ratio
- 0.35
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals had revenue of 677.56M and earned 59.01M in profits. Earnings per share was 0.80.
- Revenue
- 677.56M
- Gross Profit
- 370.15M
- Operating Income
- 77.22M
- Pretax Income
- 88.87M
- Net Income
- 59.01M
- EBITDA
- 90.42M
- Earnings Per Share (EPS)
- 0.80
Cash Flow
In the last 12 months, operating cash flow was 198.84M and capital expenditures -1.64M, giving a free cash flow of 197.20M billion.
- Operating Cash Flow
- 198.84M
- Free Cash Flow
- 197.20M
- Free Cash Flow per Share
- 2.52
Dividends & Yields
Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.61%
- Earnings Yield
- 1.45%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- 139.09%
- 50-Day Moving Average
- 81.49
- 200-Day Moving Average
- 62.60
- Relative Strength Index (RSI)
- 60.12
- Average Volume (3m)
- 661.39K
Important Dates
Kiniksa Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Kiniksa Pharmaceuticals as a current ratio of 3.79, with Debt / Equity ratio of 1.67%
- Current Ratio
- 3.79
- Quick Ratio
- 3.39
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.73
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Kiniksa Pharmaceuticals has paid 29.86M in taxes.
- Income Tax
- 29.86M
- Effective Tax Rate
- 0.34
Enterprise Valuation
Kiniksa Pharmaceuticals EV to EBITDA ratio is 52.01, with an EV/FCF ratio of 38.01.
- EV to Sales
- 7.92
- EV to EBITDA
- 52.01
- EV to Free Cash Flow
- 38.01
- EV to Operating Cash Flow
- 37.69
Balance Sheet
Kiniksa Pharmaceuticals has $568.76M in cash and marketable securities with $7.88M in debt, giving a net cash position of $560.87M billion.
- Cash & Marketable Securities
- $568.76M
- Total Debt
- $7.88M
- Net Cash
- $560.87M
- Net Cash Per Share
- $11.48
- Tangible Book Value Per Share
- $8.90
Margins
Gross margin is 54.26%, with operating margin of 13.79%, and net profit margin of 11.58%.
- Gross Margin
- 54.26%
- Operating Margin
- 13.79%
- Pretax Margin
- 15.45%
- Net Profit Margin
- 11.58%
- EBITDA Margin
- 15.23%
- EBIT Margin
- 15.03%
Analyst Forecast
The average price target for Kiniksa Pharmaceuticals is $106.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $106.20
- Price Target Upside
- 10.25% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 58.19%
- EPS Growth Forecast
- 192.34%
Scores
- Smart Score
- 9
- AI Score
- 77
